Lupin intimates of successful USFDA inspection of its Nagpur facility
Capital MarketLupin announced the successful completion of an inspection carried out by the US FDA at its Nagpur, Maharashtra, India facility. The inspection concluded without any observation. This inspection was a product specific pre-approval inspection.
Lupin's Nagpurfacility is the company's latest site and manufactures Oral Solid Dosage products. The site also houses Lupin's state of the art injectable manufacturing facility.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
